Depomed, Inc., a specialty pharmaceutical company, has entered into a settlement agreement in its ongoing patent litigation related to an Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Depomed's Zipsor (diclofenac liquid filled capsules) 25mg tablets.

The settlement permits defendant Watson Laboratories Inc. to begin selling generic Zipsor on March 24, 2022, or earlier under certain circumstances. The settlement concludes all ongoing ANDA litigation related to Zipsor.

"This settlement provides nearly seven years of continued market exclusivity for Zipsor. With settlements in place to 2024 for Gralise and 2023 for Cambia plus patents protecting Lazanda and Nucynta to 2024 and beyond, we expect to have lengthy periods of market exclusivity for every product in our portfolio," said Jim Schoeneck, president and chief executive officer of Depomed.

The settlement agreement is subject to review by the US Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the US District Court for the District of New Jersey.

Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders.